Global Pharmaceutical Platform Optimization
| Market | Visits | Bounce Rate | Pages/Visit | New Registrations | Completion Rate | Heuristic Score |
|---|---|---|---|---|---|---|
| Vietnam | 45,000 | 14.2% | 2.88 | 95 | 41% | 27/100 |
| Mexico | 17,000 | 27.65% | — | — | — | — |
| KSA | 330 organic/mo | — | — | — | — | 32/100 |
| UK | — | — | — | — | — | Best Practice |
Strongest performer with 45K visits and lowest bounce rate (14.2%). Augmentin (6,541) and Infanrix (6,004) drive significant traffic. Despite high engagement, heuristic score remains critical (27/100).
27.65% bounce rate indicates poor first impression. High variation in page performance suggests lack of standardization. Critical gaps in navigation consistency and search functionality.
Only 330 organic sessions/month, with 90.6% traffic from outside target market. Domain authority (35/100) and minimal backlinks (22) severely limit discoverability. Urgent ungated content strategy needed.
Strongest therapy area organization and navigation clarity. Use as template for global rollout of therapy-first architecture.
9-Parameter Evaluation Framework
Static carousels, generic CTAs across SA, Mexico, Vietnam. No clear differentiation or HCP-specific value hooks.
Basic product information present but lacks comprehensive clinical context, case studies, and comparative data.
Data usage moderate, but weak narrative structure. High variation in medical language quality across markets.
Highly inconsistent layouts. Missing MoA visuals, buried safety information. No standardized product page template.
58.87% of images missing alt attributes. Limited infographics, mechanism-of-action diagrams, or visual clinical data.
Poor adaptation to local HCP needs and preferences. Generic global content without regional clinical context.
Calculators, CME modules, polls, and Ask the Expert features absent or severely limited across all markets.
Weak ungated content, slow page speeds (22-27/100), failed Core Web Vitals. Only 17 keywords ranking in KSA vs 146 in US.
Basic compliance present but safety information often buried. Inconsistent placement affects trust and regulatory adherence.
58.87% of all images (498/846)
Significant issues across content
Critical gaps despite high engagement and traffic
Ranked by Impact × Feasibility
Highly inconsistent layouts across markets. Missing mechanism-of-action visuals, buried safety information, and no cohesive information architecture.
Product-first navigation rather than disease-first organization. HCPs struggle to find relevant therapeutic information quickly.
All content gated behind registration. KSA receives only 330 organic sessions/month vs 35K+ for competitors with ungated content strategies.
Page speeds at 22-27/100, accessibility score 88.8/100, 58.87% images missing alt text. Core Web Vitals failing across all metrics.
Calculators, CME modules, polls, and Ask the Expert features absent across most markets. No interactive tools to drive engagement.